Impact of CYP3A5 genotype on tacrolimus management in adult heart transplant recipients

被引：0
作者：
Pasternak, Amy [1 ]
Hong, Je-Won [1 ]
Lewis, Sarah [1 ]
机构：
[1] Univ Michigan, Coll Pharm, Ann Arbor, MI USA
来源：
PHARMACOGENETICS AND GENOMICS | 2025年 / 35卷 / 01期
关键词：
D O I：
暂无
中图分类号：
Q81 [生物工程学（生物技术）]; Q93 [微生物学];
学科分类号：
071005 ; 0836 ; 090102 ; 100705 ;
摘要：
引用
收藏
页码：35 / 36
页数：2
相关论文
共 50 条
[31]   COMPARISON OF TACROLIMUS STARTING DOSES BASED ON CYP3A5 PHENOTYPE OR GENOTYPE IN KIDNEY TRANSPLANT RECIPIENTS. [J].
Largeau, B. ;
Noble, J. ;
Longuet, H. ;
Halimi, J. ;
Buchler, M. ;
Gatault, P. ;
Marquet, P. ;
Barin-Le Guellec, C. .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2019, 105 :S102-S103
[32]   CYP3A5 GENOTYPE IS NOT RELATED TO THE INTRA-PATIENT VARIABILITY OF TACROLIMUS CLEARANCE IN RENAL TRANSPLANT RECIPIENTS [J].
Spierings, Natalia M. K. ;
Pashaee, Nilufar ;
Bouamar, Rachida ;
Hesselink, Dennis A. ;
Roodnat, Joke I. ;
van Schaik, Ron H. N. ;
Weimar, Willem ;
Holt, David W. ;
MacPhee, Iain A. M. ;
van Gelder, Teun .
TRANSPLANT INTERNATIONAL, 2011, 24 :80-81
[33]   The Effect of Weight and CYP3A5 Genotype on the Population Pharmacokinetics of Tacrolimus in Stable Paediatric Renal Transplant Recipients [J].
Agnieszka A. Prytuła ;
Karlien Cransberg ;
Antonia H. M. Bouts ;
Ron H. N. van Schaik ;
Huib de Jong ;
Saskia N. de Wildt ;
Ron A. A. Mathôt .
Clinical Pharmacokinetics, 2016, 55 :1129-1143
[34]   CYP3A5 polymorphisms in renal transplant recipients: influence on tacrolimus treatment [J].
Chen, Lucy ;
Prasad, G. V. Ramesh .
PHARMACOGENOMICS & PERSONALIZED MEDICINE, 2018, 11 :23-33
[35]   Influence of CYP3A5 Polymorphisms on Tacrolimus Dosing in Renal Transplant Recipients [J].
Kotha, Chandini ;
Sahay, Manisha .
TRANSPLANTATION, 2022, 106 (09) :S135-S135
[36]   The Clinical Impact of the C0/D Ratio and the CYP3A5 Genotype on Outcome in Tacrolimus Treated Kidney Transplant Recipients [J].
van Gelder, Teun ;
Meziyerh, Soufian ;
Swen, Jesse J. ;
de Vries, Aiko P. J. ;
Moes, Dirk Jan A. R. .
FRONTIERS IN PHARMACOLOGY, 2020, 11
[37]   Impact of the CYP3A5*1 Allele on the Pharmacokinetics of Tacrolimus in Japanese Heart Transplant Patients [J].
Uno, Takaya ;
Wada, Kyoichi ;
Matsuda, Sachi ;
Terada, Yuka ;
Oita, Akira ;
Kawase, Atsushi ;
Takada, Mitsutaka .
EUROPEAN JOURNAL OF DRUG METABOLISM AND PHARMACOKINETICS, 2018, 43 (06) :665-673
[38]   Impact of CYP3A5 phenotype on tacrolimus time in therapeutic range and clinical outcomes in pediatric renal and heart transplant recipients [J].
Leino, Abbie D. ;
Park, Jeong M. ;
Pasternak, Amy L. .
PHARMACOTHERAPY, 2021, 41 (08) :649-657
[39]   Impact of the CYP3A5*1 Allele on the Pharmacokinetics of Tacrolimus in Japanese Heart Transplant Patients [J].
Takaya Uno ;
Kyoichi Wada ;
Sachi Matsuda ;
Yuka Terada ;
Akira Oita ;
Atsushi Kawase ;
Mitsutaka Takada .
European Journal of Drug Metabolism and Pharmacokinetics, 2018, 43 :665-673
[40]   Prediction of the tacrolimus population pharmacokinetic parameters according to CYP3A5 genotype and clinical factors using NONMEM in adult kidney transplant recipients [J].
Nayoung Han ;
Hwi-yeol Yun ;
Jin-yi Hong ;
In-Wha Kim ;
Eunhee Ji ;
Su Hyun Hong ;
Yon Su Kim ;
Jongwon Ha ;
Wan Gyoon Shin ;
Jung Mi Oh .
European Journal of Clinical Pharmacology, 2013, 69 :53-63
12345